PTHS

Pelthos Therapeutics Inc

Apr 06 • 04:00PM ET

24.38

+3.98 19.51 %

Healthcare • Biotechnology • USA • AMEX

Today, 4:01 PMAnalyst optimism and high price targets drive momentum buying in PTHS shares.

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Index	-	P/E	-	EPS (ttm)	-20.77	Insider Own	12.84%	Shs Outstand	3.23M	Perf Week	8.40%
Market Cap	81.80M	Forward P/E	-	EPS next Y	-1.04	Insider Trans	-2.87%	Shs Float	2.92M	Perf Month	8.79%
Enterprise Value	98.61M	PEG	-	EPS next Q	-3.45	Inst Own	32.95%	Short Float	2.83%	Perf Quarter	-17.22%
Income	-43.32M	P/S	4.87	EPS this Y	57.58%	Inst Trans	6.00%	Short Ratio	9.91	Perf Half Y	-8.42%
Sales	16.80M	P/B	2.03	EPS next Y	89.40%	ROA	-	Short Interest	0.08M	Perf YTD	-21.35%
Book/sh	12.02	P/C	4.54	EPS next 5Y	-	ROE	-	52W High	54.29 -55.09%	Perf Year	78.77%
Cash/sh	5.37	P/FCF	-	EPS past 3/5Y	-75.48% -82.26%	ROIC	-59.28%	52W Low	9.00 170.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 142.58%	Gross Margin	62.65%	Volatility	10.27% 7.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.87	EPS Y/Y TTM	-12.49%	Oper. Margin	-193.09%	ATR (14)	2.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	-	Profit Margin	-257.93%	RSI (14)	56.28	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.03	EPS Q/Q	-134.73%	SMA20	7.34%	Beta	4.00	Target Price	57.14
Payout	-	Debt/Eq	0.90	Sales Q/Q	-	SMA50	5.78%	Rel Volume	3.45	Prev Close	20.40
Employees	92	LT Debt/Eq	0.88	Earnings	Mar 19 BMO	SMA200	-2.21%	Avg Volume	8.32K	Price	24.38
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-85.84% 3.28%	Trades		Volume	28,715	Change	19.51%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-27-26	Initiated	Piper Sandler	Overweight	$48
Dec-03-25	Initiated	Lake Street	Buy	$50
Dec-03-25	Initiated	H.C. Wainwright	Buy	$60
Nov-25-25	Initiated	Roth Capital	Buy	$57
Sep-02-25	Initiated	Oppenheimer	Outperform	$50

Mar-31-26 08:30AM	Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain (GlobeNewswire)
Mar-19-26 03:00PM	Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... (GuruFocus.com)
06:30AM	Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-12-26 08:30AM	Pelthos Therapeutics to Present at 38th Annual ROTH Conference (GlobeNewswire)
Mar-09-26 08:30AM	Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire)
08:00AM	Loading…
Feb-23-26 08:00AM	Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.04%
Jan-13-26 08:30AM	Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance (GlobeNewswire)
Jan-05-26 07:30AM	Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice (GlobeNewswire) -9.03%
Dec-23-25 05:57PM	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn (GlobeNewswire)
Dec-04-25 07:00AM	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% (GlobeNewswire)
Dec-02-25 08:00AM	Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 06:45AM	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -7.27%
Nov-07-25 08:00AM	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing (GlobeNewswire) -8.07%
Nov-05-25 08:00AM	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 (GlobeNewswire) +6.47%
Oct-09-25 08:00AM	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum (GlobeNewswire) -7.89%
08:30AM	Loading…
Sep-08-25 08:30AM	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +13.96%
Sep-02-25 08:00AM	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire) -5.03%
Aug-18-25 08:00AM	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update (GlobeNewswire)
Jul-10-25 08:00AM	Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum (GlobeNewswire) +60.78%
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire) +22.22%
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malamut Richard	Director	Apr 02 '26	Sale	20.92	590	12,340	27,422	Apr 06 05:03 PM
Friedberg Ezra M	Director	Apr 02 '26	Sale	20.92	558	11,671	82,027	Apr 06 05:03 PM
Pauls Matthew	Director	Apr 02 '26	Sale	20.92	786	16,439	15,150	Apr 06 05:02 PM
Greenleaf Peter	Director	Apr 02 '26	Sale	20.92	797	16,670	24,681	Apr 06 05:01 PM
Pauls Matthew	Director	Oct 02 '25	Option Exercise	0.00	2,123	0	10,616	Dec 12 05:01 PM
Pauls Matthew	Director	Jul 02 '25	Option Exercise	0.00	8,493	0	8,493	Dec 12 05:01 PM
Friedberg Ezra M	Director	Nov 25 '25	Sale	28.03	10,000	280,280	30,000	Nov 26 12:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTHS

Pelthos Therapeutics Inc

Upgrade your Finviz experience